TY  - JOUR
AU  - Gravalos, C.
AU  - Rodriguez, C.
AU  - Sabino, A.
AU  - Segui, M. A.
AU  - Virizuela, J. A.
AU  - Carmona, A.
AU  - Cassinello, J.
AU  - Isla, D.
AU  - Jara, C.
AU  - Martin, M.
PY  - 2016
DO  - 10.1007/s12094-016-1590-1
SN  - 1699-048X
UR  - http://hdl.handle.net/10668/18655
T2  - Clinical & translational oncology
AB  - Bone metastases are common in many advanced solid tumours, being breast, prostate, thyroid, lung, and renal cancer the most prevalent. Bone metastases can produce skeletal-related events (SREs), defined as pathological fracture, spinal cord...
LA  - en
PB  - Springer international publishing ag
KW  - Biphosphonates
KW  - Bone metastases
KW  - Denosumab
KW  - Skeletal-related events (SREs)
KW  - Radium 223
KW  - Zoledronic acid
KW  - Placebo-controlled trial
KW  - Randomized controlled-trial
KW  - Refractory prostate-cancer
KW  - Long-term efficacy
KW  - Breast-cancer
KW  - Zoledronic acid
KW  - Skeletal metastases
KW  - Double-blind
KW  - Lung-cancer
KW  - Scintigraphy
TI  - SEOM Clinical Guideline for bone metastases from solid tumours (2016)
TY  - research article
VL  - 18
ER  -